31969338|t|Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
31969338|a|PURPOSE: Treatment failure from drug resistance is the primary reason for relapse in acute lymphoblastic leukemia (ALL). Improving outcomes by targeting mechanisms of drug resistance is a potential solution. PATIENTS AND METHODS: We report results investigating the epigenetic modulators decitabine and vorinostat with vincristine, dexamethasone, mitoxantrone, and PEG-asparaginase for pediatric patients with relapsed or refractory B-cell ALL (B-ALL). Twenty-three patients, median age 12 years (range, 1-21) were treated in this trial. RESULTS: The most common grade 3-4 toxicities included hypokalemia (65%), anemia (78%), febrile neutropenia (57%), hypophosphatemia (43%), leukopenia (61%), hyperbilirubinemia (39%), thrombocytopenia (87%), neutropenia (91%), and hypocalcemia (39%). Three subjects experienced dose-limiting toxicities, which included cholestasis, steatosis, and hyperbilirubinemia (n = 1); seizure, somnolence, and delirium (n = 1); and pneumonitis, hypoxia, and hyperbilirubinemia (n = 1). Infectious complications were common with 17 of 23 (74%) subjects experiencing grade >=3 infections including invasive fungal infections in 35% (8/23). Nine subjects (39%) achieved a complete response (CR + CR without platelet recovery + CR without neutrophil recovery) and five had stable disease (22%). Nine (39%) subjects were not evaluable for response, primarily due to treatment-related toxicities. Correlative pharmacodynamics demonstrated potent in vivo modulation of epigenetic marks, and modulation of biologic pathways associated with functional antileukemic effects. CONCLUSIONS: Despite encouraging response rates and pharmacodynamics, the combination of decitabine and vorinostat on this intensive chemotherapy backbone was determined not feasible in B-ALL due to the high incidence of significant infectious toxicities. This study is registered at http://www.clinicaltrials.gov as NCT01483690.
31969338	0	10	Decitabine	Chemical	MESH:D000077209
31969338	15	25	Vorinostat	Chemical	MESH:D000077337
31969338	66	94	Acute Lymphoblastic Leukemia	Disease	MESH:D054198
31969338	98	102	TACL	Disease	
31969338	201	229	acute lymphoblastic leukemia	Disease	MESH:D054198
31969338	324	332	PATIENTS	Species	9606
31969338	404	414	decitabine	Chemical	MESH:D000077209
31969338	419	429	vorinostat	Chemical	MESH:D000077337
31969338	435	446	vincristine	Chemical	MESH:D014750
31969338	448	461	dexamethasone	Chemical	MESH:D003907
31969338	463	475	mitoxantrone	Chemical	MESH:D008942
31969338	481	497	PEG-asparaginase	Chemical	MESH:C042705
31969338	512	520	patients	Species	9606
31969338	549	559	B-cell ALL	Disease	MESH:D015456
31969338	561	566	B-ALL	Disease	MESH:D054198
31969338	582	590	patients	Species	9606
31969338	689	699	toxicities	Disease	MESH:D064420
31969338	709	720	hypokalemia	Disease	MESH:D007008
31969338	728	734	anemia	Disease	MESH:D000740
31969338	742	761	febrile neutropenia	Disease	MESH:D064147
31969338	769	785	hypophosphatemia	Disease	MESH:D017674
31969338	793	803	leukopenia	Disease	MESH:D007970
31969338	811	829	hyperbilirubinemia	Disease	MESH:D006932
31969338	837	853	thrombocytopenia	Disease	MESH:D013921
31969338	861	872	neutropenia	Disease	MESH:D009503
31969338	884	896	hypocalcemia	Disease	MESH:D006996
31969338	945	955	toxicities	Disease	MESH:D064420
31969338	972	983	cholestasis	Disease	MESH:D002779
31969338	985	994	steatosis	Disease	MESH:D005234
31969338	1000	1018	hyperbilirubinemia	Disease	MESH:D006932
31969338	1028	1035	seizure	Disease	MESH:D012640
31969338	1037	1047	somnolence	Disease	MESH:D006970
31969338	1053	1061	delirium	Disease	MESH:D003693
31969338	1075	1086	pneumonitis	Disease	MESH:D011014
31969338	1088	1095	hypoxia	Disease	MESH:D000860
31969338	1101	1119	hyperbilirubinemia	Disease	MESH:D006932
31969338	1129	1153	Infectious complications	Disease	MESH:D003141
31969338	1218	1228	infections	Disease	MESH:D007239
31969338	1239	1265	invasive fungal infections	Disease	MESH:D000072742
31969338	1522	1532	toxicities	Disease	MESH:D064420
31969338	1797	1807	decitabine	Chemical	MESH:D000077209
31969338	1812	1822	vorinostat	Chemical	MESH:D000077337
31969338	1894	1899	B-ALL	Disease	MESH:D054198
31969338	1941	1962	infectious toxicities	Disease	MESH:D003141
31969338	Positive_Correlation	MESH:D000077337	MESH:D006970
31969338	Cotreatment	MESH:C042705	MESH:D000077337
31969338	Negative_Correlation	MESH:C042705	MESH:D054198
31969338	Cotreatment	MESH:D000077337	MESH:D014750
31969338	Positive_Correlation	MESH:D000077209	MESH:D006932
31969338	Cotreatment	MESH:D000077209	MESH:D008942
31969338	Negative_Correlation	MESH:D000077337	MESH:D015456
31969338	Positive_Correlation	MESH:D000077337	MESH:D012640
31969338	Positive_Correlation	MESH:D000077337	MESH:D005234
31969338	Positive_Correlation	MESH:D000077337	MESH:D003141
31969338	Negative_Correlation	MESH:D000077209	MESH:D015456
31969338	Negative_Correlation	MESH:D008942	MESH:D015456
31969338	Negative_Correlation	MESH:D008942	MESH:D054198
31969338	Positive_Correlation	MESH:D000077209	MESH:D003693
31969338	Positive_Correlation	MESH:D000077209	MESH:D003141
31969338	Positive_Correlation	MESH:D000077337	MESH:D002779
31969338	Positive_Correlation	MESH:D000077337	MESH:D013921
31969338	Negative_Correlation	MESH:D003907	MESH:D054198
31969338	Negative_Correlation	MESH:D000077337	MESH:D054198
31969338	Positive_Correlation	MESH:D000077337	MESH:D003693
31969338	Positive_Correlation	MESH:D000077209	MESH:D002779
31969338	Negative_Correlation	MESH:C042705	MESH:D015456
31969338	Positive_Correlation	MESH:D000077337	MESH:D006932
31969338	Negative_Correlation	MESH:D014750	MESH:D015456
31969338	Negative_Correlation	MESH:D014750	MESH:D054198
31969338	Negative_Correlation	MESH:D000077209	MESH:D054198
31969338	Positive_Correlation	MESH:D000077337	MESH:D011014
31969338	Cotreatment	MESH:D000077337	MESH:D008942
31969338	Positive_Correlation	MESH:D000077337	MESH:D006996
31969338	Negative_Correlation	MESH:D003907	MESH:D015456
31969338	Cotreatment	MESH:D000077209	MESH:D000077337

